Organisation paid for research Program year 2025 Source: CMS Open Payments

Vistar Eye Center Inc

Neither a doctor nor a teaching hospital

Research payments

$567,017

219 payments

Through program year 2025, Vistar Eye Center Inc is reported as receiving $567,017 in research payments, across 219 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$135,616	21
2024	Research	$23,695	6
2023	Research	$8,710	5
2022	Research	$24,449	8
2021	Research	$108,264	118
2020	Research	$165,926	38
2019	Research	$100,356	23

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $330,396 78 payments
Ocular Therapeutix, Inc. $120,554 18 payments
Alcon Research LLC $70,020 110 payments
AbbVie, Inc. $21,078 6 payments
RxSight Inc $20,000 5 payments
ANI Pharmaceuticals, Inc. $3,469 1 payment
Regeneron Pharmaceuticals, Inc. $1,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $120,554 18 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $111,237 20 payments
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS) $59,460 12 payments
Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $59,005 106 payments
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $48,165 19 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $47,940 12 payments
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $37,015 12 payments
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma Gold-Standard Pathway Study GPS $24,539 2 payments
Pmcs-002 $20,000 5 payments
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma $10,093 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.